Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

NCT07445347 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.

NCT NCT07445347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07445347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
Lead sponsor
Poitiers University Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 15, 2025
Completion date
November 30, 2026
Enrollment
111 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, hereditary hemorrhagic telangiectasia (hht), pulmonary hypertension